Krieger S |
Multiple sclerosis therapeutic pipeline: opportunities and challenges. |
|
Mt. Sinai J. Med. |
pmid:21425264
|
Derwenskus J |
Current disease-modifying treatment of multiple sclerosis. |
|
Mt. Sinai J. Med. |
pmid:21425262
|
Huizinga R and Voyer T |
New paradigms in immunosuppression. |
|
CANNT J |
pmid:14596200
|
Yopp AC et al. |
Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. |
|
Clin Transplant |
pmid:17100731
|
Chen S et al. |
FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. |
|
Transplant. Proc. |
pmid:11750317
|
Chun J and Hartung HP |
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. |
|
Clin Neuropharmacol |
pmid:20061941
|
Troncoso P et al. |
FTY 720 prevents ischemic reperfusion damage in rat kidneys. |
|
Transplant. Proc. |
pmid:11267102
|
Fu F et al. |
FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. |
|
Transplant. Proc. |
pmid:11267010
|
Chueh SC et al. |
FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. |
|
Transplant. Proc. |
pmid:11266948
|
Brinkmann V et al. |
FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. |
|
Transplant. Proc. |
pmid:11266942
|